Lessons learned from External Quality Assessment for BRCA and other HRR gene variants for ovarian and prostate cancer
This white paper distils the key lessons from the 2023 EMQN worldwide External Quality Assessment (EQA) scheme, helping genetic testing laboratories improve the accuracy, consistency, and clinical relevance of BRCA and HRR gene variant testing for ovarian and prostate cancer. It summarises common challenges observed across participating labs and provides practical guidance on variant detection, […]
Lessons learned from the 2024 External Quality Assessment (EQA) scheme for molecular testing in Lung (NSCLC) cancer tissue samples.
The EQA scheme for molecular testing in non-small cell lung cancer (NSCLC) in tissue has been running for 14 years and currently has a global participation of 350 laboratories in 32 countries. In 2024 it comprised two sub-schemes:• Mandatory testing for common biomarkers (CB) in the EGFR, KRAS and BRAF genes• Optional testing for new […]